U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H44O2
Molecular Weight 400.6371
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CALCIFEDIOL ANHYDROUS

SMILES

[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C)[C@H](C)CCCC(C)(C)O

InChI

InChIKey=JWUBBDSIWDLEOM-DTOXIADCSA-N
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1

HIDE SMILES / InChI
Molecular Formula C27H44O2
Molecular Weight 400.6371
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 2
Optical Activity UNSPECIFIED

Description

Calcifediol (25-Hydroxyvitamin D3 or 25-hydroxycholecalciferol) is a biologically active vitamin D3 metabolite. It is concluded that the liver is the major if not the only physiologic site of hydroxylation of vitamin D3 into calcifediol. Calcifediol is a prohormone of the active form of vitamin D3, calcitriol (1,25-dihydroxyvitamin D3). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis. RAYALDEE (calcifediol) extended-release capsules is indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease.

CNS Activity

Originator

Approval Year

1980
57
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
RAYALDEE

Approved Use

Calcifediol indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL

Launch Date

2016
Primary
Approved
8429
CALDEROL

Approved Use

Unknown

Launch Date

1980
Primary
Approved
8429
CALDEROL

Approved Use

Unknown

Launch Date

1980
Primary
Approved
8429
CALDEROL

Approved Use

Unknown

Launch Date

1980
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73.2 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24516879/
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1704.4 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24516879/
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 day
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24516879/
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24516879/
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Other AEs: Anemia, Nasopharyngitis...
Other AEs:
Anemia (4.9%)
Nasopharyngitis (4.9%)
Blood creatinine increased (4.9%)
Dyspnea (4.2%)
Cough (3.5%)
Cardiac failure congestive (3.5%)
Constipation (3.2%)
Bronchitis (2.8%)
Hyperkalemia (2.5%)
Osteoarthritis (2.1%)
Hyperuricemia (1.8%)
Contusion (1.8%)
Pneumonia (1.4%)
Chronic obstructive pulmonary disease (1.4%)
Calcium increased serum (4.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Chronic obstructive pulmonary disease 1.4%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Pneumonia 1.4%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Contusion 1.8%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Hyperuricemia 1.8%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Osteoarthritis 2.1%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Hyperkalemia 2.5%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Bronchitis 2.8%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Constipation 3.2%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Cardiac failure congestive 3.5%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Cough 3.5%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Calcium increased serum 4.2%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Dyspnea 4.2%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Anemia 4.9%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Blood creatinine increased 4.9%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Nasopharyngitis 4.9%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP27B1
3

UGT enzymes
27
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGT enzymes
27
 likely
CYP27B1
3
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
AHH Chemical co.,ltd
MT-48884
http://www.ahhchemical.com/product/MT-48884.html
Achemtek
0102-017034
http://www.achemtek.com/19356-17-3
ApexBio Technology
B2140
http://www.apexbt.com/calcifediol-26843.html
ApexBio Technology
B1056
http://www.apexbt.com/calcifediol-d6.html
Aurora Fine Chemicals LLC
A17.876.862
http://online.aurorafinechemicals.com/info?ID=A17.876.862
Aurum Pharmatech LLC
W-5159
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5159
AvaChem Scientific
2558
http://www.avachem.com/productSearch.asp?2558
BioCrick
BCC4949
http://www.biocrick.com/Calcifediol-BCC4949.html
BioSynth
W-201718
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/W-201718.html
Boerchem
BC219279
http://www.boerchem.com/?product_36973.html
Capot Chemical
18824
http://www.capotchem.com/en/18824.htm
Capot Chemical
PubChem18824
http://www.capotchem.com/en/18824.htm
Chem Scene
CS-0800
http://www.chemscene.com/19356-17-3.html
ChemFaces
CFN94017
http://www.chemfaces.com/natural/25-Hydroxycholecalciferol-monohydrate-CFN94017.html
ChemMol
44005951
http://www.chemmol.com/chemmol/44005951.html
Chemspace
CSSB00032005042
https://chem-space.com/CSSB00032005042
Chiralblock Biosciences
CB11410
http://www.chiralblock.com/products/63283-36-3.html
EMD Biosciences
679102
http://www.emdbiosciences.com/product/679102
EMD Millipore
679102
http://www.emdbiosciences.com/product/679102
Glentham Life Sciences
GV7732
http://www.glentham.com/products/product/GV7732/
Lab Network
LN00197433
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00197433
MedChem Express
HY-32351
https://www.medchemexpress.com/Calcifediol.html
MuseChem
R028208
https://www.musechem.com/product/R028208.html
OChem
8414
http://www.ocheminc.com/index.php?act=psearch&pid=356C173
Parchem
28428
http://www.parchem.com/chemical-supplier-distributor/Calcifediol-018428.aspx
Selleck Chemicals
S1469
http://www.selleckchem.com/products/Calcifediol.html
Sigma-Aldrich
739642_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/739642?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
739650_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/739650?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
739669_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/739669?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
17938_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/17938?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1086108_USP
https://www.sigmaaldrich.com/catalog/product/usp/1086108?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Tocris
4036
https://www.tocris.com/products/calcifediol_4036
VladaChem
VL273145-10MG
https://www.vladachem.com/product.php?products=19356-17-3
Yuhao Chemical
XJ4467
http://www.chemyuhao.com/19356-17-3.html
abcr GmbH
AB503647
http://www.abcr.com/shop/en/AB503647
abcr GmbH
AB443287
http://www.abcr.de/shop/en/AB443287
eNovation Chemicals
D699759
https://www.enovationchem.com/ProductDetails.asp?ProductID=D699759
eNovation Chemicals
D763693
https://www.enovationchem.com/ProductDetails.asp?ProductID=D763693
eNovation Chemicals
Y0974281
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974281
iChemical
EBD2201904
http://www.ichemical.com/products/19356-17-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Vitamin D3 compounds regulate human immunodeficiency virus type 1 replication in U937 monoblastoid cells and in monocyte-derived macrophages.
1993 Feb
Overview of general physiologic features and functions of vitamin D.
2004 Dec
Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells.
2005 Dec 30
Androgen enhances the antiproliferative activity of vitamin D3 by suppressing 24-hydroxylase expression in LNCaP cells.
2006 Apr
Patents

Patents

JP4806519B2
14
JPH0586021A
3
JPS62263110A
3

Sample Use Guides

In Vivo Use Guide
The initial dose of RAYALDEE (calcifediol) extended-release capsules is 30 mcg administered orally once daily at bedtime. Serum calcium should be below 9.8 mg/dL before initiating treatment. Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and intact parathyroid hormone (PTH) 3 months after starting therapy or changing dose. Increase the dose to 60 mcg once daily after 3 months if intact PTH is above the treatment goal. Ensure serum calcium is below 9.8 mg/dL, phosphorus is below 5.5 mg/dL and 25-hydroxyvitamin D is below 100 ng/mL before increasing the dose. Suspend dosing if intact PTH is persistently abnormally low, serum calcium is consistently above the normal range or serum 25­ hydroxyvitamin D is consistently above 100 ng/mL
Route of Administration: Oral
In Vitro Use Guide
Vitamin D metabolites down-regulated stimulated IL-8 only in those hyperinflammatory monocyte-derived macrophages, and only when used at high doses (>100 nM for Calcifediol).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:22 GMT 2023
Edited
by admin
on Fri Dec 15 15:02:22 GMT 2023
Record UNII
T0WXW8F54E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIFEDIOL ANHYDROUS
Common Name English
CALCIDIOL
Common Name English
CALCIFEDIOL, ANHYDROUS
Common Name English
CALCIFEDIOL,ANHYDROUS
VANDF  
Common Name English
CALCIFEDIOL [MI]
Common Name English
calcifediol [INN]
Common Name English
CALCIFEDIOL,ANHYDROUS [VANDF]
Common Name English
Classification Tree Code System Code
LOINC 83071-1
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
NDF-RT N0000175908
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
NCI_THESAURUS C39713
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
LOINC 68438-1
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
LOINC 62292-8
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
WHO-ATC A11CC06
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
LOINC 83070-3
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
Code System Code Type Description
DAILYMED
T0WXW8F54E
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
SMS_ID
100000081591
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
INN
3057
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
CHEBI
17933
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
MERCK INDEX
m2911
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB00146
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
PUBCHEM
5283731
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
NCI_THESAURUS
C77155
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
EVMPD
SUB32968
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
ALTERNATIVE
EVMPD
SUB06045MIG
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID0022721
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
RXCUI
1855064
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
FDA UNII
T0WXW8F54E
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
ECHA (EC/EINECS)
242-990-9
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
CAS
19356-17-3
Created by admin on Fri Dec 15 15:02:22 GMT 2023 , Edited by admin on Fri Dec 15 15:02:22 GMT 2023
PRIMARY
Related Record Type Details
Structure of CALCIFEDIOL
SOLVATE->ANHYDROUS
Structure of D6-25-HYDROXYVITAMIN D3
LABELED -> NON-LABELED
Structure of CALCIFEDIOL
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of Cholecalciferol
PARENT -> METABOLITE ACTIVE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966